RayKnowChina Research Map
Shortlist0

GuangzhouSun Yat-sen University

Zhongshan Ophthalmic Center

中山大学中山眼科中心

Listed for 5 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Zhongshan Ophthalmic Center

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Retinoblastoma视网膜母细胞瘤25 papers led1 open trial led
  2. Neuroblastoma神经母细胞瘤0 papers led
  3. Neuromyelitis optica spectrum disorder视神经脊髓炎谱系疾病4 papers led
  4. Behçet disease白塞病7 papers led
  5. Leber hereditary optic neuropathyLeber 遗传性视神经病变3 papers led

Not listed for: Nasopharyngeal carcinoma, Oesophageal squamous cell carcinoma, Hepatocellular carcinoma, Stomach cancer, Hepatoblastoma, Chordoma, Osteosarcoma, Gastrointestinal stromal tumour, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 25 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 8.3%.

Papers led
25
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 8820212022: 3320222023: 4420232024: 5520242025: 552025

8 hospitals in Guangzhou for retinoblastoma196 hospitals in China for retinoblastoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Adjuvant Chemotherapy for High-risk Postenucleation Retinoblastoma
    Phase
    Phase 3
    Started
    2020-11
    Registry
    NCT05080010

    Age not stated (registered criteria)

    Led by Zhongshan Ophthalmic CenterGuangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmologyMedical oncology

Over half of these papers are lab or animal studies.

Papers it led25
  1. Loss of ELF2 drives topotecan resistance in retinoblastoma revealed by genome-wide CRISPR-Cas9 screening.2025Cell death & disease
  2. MTHFD2 drives retinoblastoma progression via Notch signaling activation: Implications for targeted pediatric ocular cancer therapy.2025Experimental eye research
  3. Targeting MCM6 Enhances Melphalan Chemosensitivity in Retinoblastoma by Modulating DNA Damage Response.2025Investigative ophthalmology & visual science
  4. SOX4 as a Key Oncogene Driving Tumor Invasion in Retinoblastoma.2025Investigative ophthalmology & visual science
  5. The role of lactate metabolism in retinoblastoma tumorigenesis and ferroptosis resistance.2025Tissue & cell
  6. Comprehensive identification of pathogenic variants in retinoblastoma by long- and short-read sequencing.2024Cancer letters
  7. Single-cell transcriptomics enable the characterization of local extension in retinoblastoma.2024Communications biology
  8. PRMT1 mediates the proliferation of Y79 retinoblastoma cells by regulating the p53/p21/CDC2/cyclin B pathway.2024Experimental eye research
  9. Heterogeneous Expression Patterns of the Minichromosome Maintenance Complex Members in Retinoblastoma Unveil Its Clinical Significance.2024Investigative ophthalmology & visual science
  10. Three vs 6 Cycles of Chemotherapy for High-Risk Retinoblastoma: A Randomized Clinical Trial.2024JAMA
  11. Polyester 5-0 suture for porous implant placement after retinoblastoma enucleation: analysis of 120 sockets.2023BMC ophthalmology
  12. Expression of YAP suppresses cell proliferation and elevates the sensitivity of chemotherapy in retinoblastoma cells through lipid-peroxidation induced ferroptosis.2023Chinese clinical oncology
  13. EZH2 Expression in Retinoblastoma: A Potential Therapeutic Target.2023Ophthalmic research
  14. Generation and characterization of two induced pluripotent stem cell lines from conjunctiva of a retinoblastoma patient.2023Stem cell research
  15. Single-cell characterization of malignant phenotypes and microenvironment alteration in retinoblastoma.2022Cell death & disease
  16. Kruppel-like factor 2 acts as a tumor suppressor in human retinoblastoma.2022Experimental eye research
  17. Bioinformatics Analysis and Experimental Identification of Immune-Related Genes and Immune Cells in the Progression of Retinoblastoma.2022Investigative ophthalmology & visual science
  18. Targeting of histone methyltransferase DOT1L plays a dual role in chemosensitization of retinoblastoma cells and enhances the efficacy of chemotherapy.2021Cell death & disease
  19. Retinoblastoma cell-derived exosomes promote angiogenesis of human vesicle endothelial cells through microRNA-92a-3p.2021Cell death & disease
  20. Ubiquitination-Related miRNA-mRNA Interaction Is a Potential Mechanism in the Progression of Retinoblastoma.2021Investigative ophthalmology & visual science
  21. Chromatin regulators in retinoblastoma: Biological roles and therapeutic applications.2021Journal of cellular physiology
  22. Efficient assembly of nanopore reads via highly accurate and intact error correction.2021Nature communications
  23. Exosomes derived from retinoblastoma cells enhance tumour deterioration by infiltrating the microenvironment.2021Oncology reports
  24. Therapeutic Targeting PLK1 by ON-01910.Na Is Effective in Local Treatment of Retinoblastoma.2021Oncology research
  25. RNA Sequencing and Bioinformatic Analysis on Retinoblastoma Revealing that Cell Cycle Deregulation Is a Key Process in Retinoblastoma Tumorigenesis.2021Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde
Earlier papers (2016–2020)13
  1. Effectiveness of intravitreal chemotherapy-assisted endoresection in monocular patients with group D retinoblastoma.2020BMC cancer
  2. UHRF1 downmodulation enhances antitumor effects of histone deacetylase inhibitors in retinoblastoma by augmenting oxidative stress-mediated apoptosis.2020Molecular oncology
  3. Artesunate induces mitochondria-mediated apoptosis of human retinoblastoma cells by upregulating Kruppel-like factor 6.2019Cell death & disease
  4. Associations among Socioeconomic Factors, Lag Time, and High-Risk Histopathologic Features in Eyes Primarily Enucleated for Retinoblastoma.2019Current eye research
  5. Identification of stemness in primary retinoblastoma cells by analysis of stem-cell phenotypes and tumorigenicity with culture and xenograft models.2019Experimental cell research
  6. Tetramethylpyrazine downregulates transcription of the CXC receptor 4 (CXCR4) via nuclear respiratory factor‑1 (Nrf‑1) in WERI‑Rb1 retinoblastoma cells.2019Oncology reports
  7. UHRF1 depletion sensitizes retinoblastoma cells to chemotherapeutic drugs via downregulation of XRCC4.2018Cell death & disease
  8. Regulated differentiation of WERI-Rb-1 cells into retinal neuron-like cells.2017International journal of molecular medicine
  9. An optimized gene transfection system in WERI-Rb1 cells.2017International journal of molecular medicine
  10. Tetramethylpyrazine-mediated regulation of CXCR4 in retinoblastoma is sensitive to cell density.2017Molecular medicine reports
  11. Functional dissection of the role of UHRF1 in the regulation of retinoblastoma methylome.2017Oncotarget
  12. The Potential Benefit of Three vs. Six Cycles of Carboplatin, Etoposide, and Vincristine in Postenucleation High-Risk Patients with IRSS Stage I Retinoblastoma.2016Current eye research
  13. Thrombospondin-1 might be a therapeutic target to suppress RB cells by regulating the DNA double-strand breaks repair.2016Oncotarget
All its trials on ClinicalTrials.gov, any status5
  1. Adjuvant Chemotherapy for High-risk Postenucleation RetinoblastomaRecruitingNCT05080010Lead (inferred)Phase 3Start 2020-11
  2. Efficacy Study of Lucentis in the Treatment of RetinoblastomaStatus unknownNCT01899066Lead (inferred)Phase 2Start 2013-07
  3. Adjuvant Chemotherapy for High-risk Retinoblastoma After EnucleationStatus unknownNCT01906814Lead (inferred)Phase 3Start 2013-08
  4. Attention to Retinoblastoma Diagnosed in the Trauma SettingCompletedNCT03764930Lead (inferred)Start 2013-01
  5. Carboplatin Periocular Injection for RetinoblastomaStatus unknownNCT02137928Lead (inferred)Phase 3Start 2006-01

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led no English-language PubMed papers on neuroblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

23 hospitals in Guangzhou for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. A Baby with Raccoon Eyes.2020Ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

Neuromyelitis optica spectrum disorder

视神经脊髓炎谱系疾病

Led 4 of the 485 English-language PubMed papers on neuromyelitis optica spectrum disorder with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 0020232024: 0020242025: 112025

9 hospitals in Guangzhou for neuromyelitis optica spectrum disorder67 hospitals in China for neuromyelitis optica spectrum disorder

No open trial on neuromyelitis optica spectrum disorder lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesOptic nerve & visionAntibodies & diagnosisImaging
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 7 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 2.9%.

Papers led
7
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 3320232024: 1120242025: 222025

7 hospitals in Guangzhou for Behçet disease149 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led 3 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 5.8%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 112025

1 hospital in Guangzhou for Leber hereditary optic neuropathy32 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

中山大学中山眼科中心

Zhongshan Ophthalmic Center

广州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR Wikidata
Zhongshan Ophthalmic Center of Sun Yat-sen University; Zhongshan Ophthalmic Centre; ZOC; Zhongshan Ophthalmic Center, Sun Yat-sen University; 中山大学眼科中心

Suggest a correctionDownload the data